20 June
2024
PureTech Health plc
PureTech Announces Change of
Board Role
Raju Kucherlapati,
PhD, distinguished Professor of Medicine at Harvard Medical School,
has transitioned to the role of Chair of the Board of Directors on
a permanent basis
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics
company dedicated to changing the lives of patients with
devastating diseases, today announces that Raju
Kucherlapati, PhD, has been appointed Chair of the Board of
Directors, effective immediately, following his role as interim
Chair since June 2023.
"On behalf of the Board, I am
delighted to welcome Raju as the Chair on a permanent basis," said
Bharatt Chowrira, PhD, JD, Chief Executive Officer of PureTech.
"Raju's exceptional leadership and strategic vision have been
instrumental to PureTech's innovation and success, particularly
over the last year while he served as interim Chair. The Board has
carefully considered Raju's skills, knowledge and expertise, as
well as his long-term involvement in the evolution of PureTech and
his exemplary leadership during his tenure as interim Chair. The
Board determined that Raju's skills and in-depth knowledge of
PureTech will be valuable over the coming years as PureTech
continues to grow and evolve. Raju continues to exercise objective
judgement and promote constructive challenge in the Board's
decision-making process. I look forward to continuing to work
together and benefitting from Raju's wise counsel as PureTech
enters an exciting period of growth, with multiple catalysts that
can deliver value to patients and shareholders."
Dr. Kucherlapati commented: "It has
been an honor to serve as interim Chair of PureTech at such an
exciting time for the business. The Company successfully delivered
against its milestones in 2023 and remains dedicated to identifying
and developing medicines with the potential to transform lives. I
look forward to continuing in my role as Chair and leveraging my
expertise, alongside the rest of the Board, to guide the Company
going forward."
Dr. Kucherlapati has served as a
member of PureTech's Board of Directors since 2014. He is currently
Chair of the Board's Nomination Committee and sits on the Audit and
Remuneration Committees. Dr. Kucherlapati will continue his current
Board committee responsibilities until a replacement is identified
at an appropriate time. The Company is actively engaged in a search
to expand its independent Board membership and has had several
promising conversations. An update will be provided in due
course.
Dr. Kucherlapati is the Paul C. Cabot
Professor of Genetics and Professor of Medicine at Harvard Medical
School and currently serves on the Board of Directors of KEW Inc.
He was a founder and formerly a board member of Abgenix (acquired
by Amgen for $2.2 billion), Cell Genesys and Millennium
Pharmaceuticals (acquired by Takeda for $8.8 billion). He was the
first scientific director of the Harvard-Partners Center for
Genetics and Genomics. He is a fellow of the American Association
for the Advancement of Science and a member of the National Academy
of Medicine. Dr. Kucherlapati received his PhD from the University
of Illinois. He trained at Yale and has held faculty positions at
Princeton University, University of Illinois College of Medicine
and the Albert Einstein College of Medicine. He was a member of the
presidential commission for the study of bioethical issues during
the Obama administration.
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded Entities.
PureTech's R&D engine has resulted in the development of 29
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech
or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All
of the underlying programs and platforms that resulted in this
pipeline of therapeutic candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points.
For more information, visit
www.puretechhealth.com
or connect with us on X (formerly Twitter)
@puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
statements that are or may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation those related to Seaport's
development plans and our future prospects, developments and
strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the
caption "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2023, filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the Company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US
Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com
